The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.

Methods and compositions for synchronizing the time of insemination in gilts are provided. More particularly, methods and compositions for synchronizing the time of insemination in gilts using a gonadotropin-releasing hormone and a hormone for synchronizing estrus are provided.

Methods and compositions for synchronizing the time of insemination in gilts are provided. More particularly, methods and compositions for synchronizing the time of insemination in gilts using a gonadotropin-releasing hormone and a hormone for synchronizing estrus are provided.

A method for non-surgical neutering or castration of a non-human mammal for AAV-mediated delivery of an anti-GnRH polypeptide to a non-human animal is described. More particularly, the animal is administered an adeno-associated virus (AAV) vector having an AAV capsid having packaged therein nucleic acid sequences comprising an AAV 5′ inverted terminal repeat (ITR), a sequence encoding a polypeptide which specifically binds gonadotropin releasing hormone (GnRH) under control of regulatory sequences which direct expression of the polypeptide, and an AAV 3′ ITR. A composition comprising the AAV-anti-GnRH may also be used for inhibiting tumor growth in a mammal with a cancer responsive to gonadal steroid hormones.

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:

##STR00001##

wherein R.sub.1a, R.sub.1b, R.sub.1c, R.sub.1d, R.sub.2, R.sub.2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

A composition for sustained-release injection comprising deslorelin, can prevent initial over-release by adjusting the release rate of deslorelin at a target site and can exhibit the effect of deslorelin for 1 month or more by being exposed in an amount enough to show the effect of deslorelin. Further, the microparticles can prepare microparticles that have a uniform particle size and are capable of exhibiting the effect of continuously releasing deslorelin for a long time.

Disclosed are eutectic form A of Elagolix and pyrimethamine, a preparation method therefor and a use thereof. Using Cu-Kα radiation, eutectic form A has characteristic peaks represented by a 20 degree at 8.1±0.2°, 12.2±0.2°, 13.3±0.2° and 21.1±0.2° in an X-ray powder diffraction. Eutectic form A has a high purity, a good light radiation stability, a high temperature stability, a high humidity stability and an accelerated stability, is easy to store, and has a slow moisture absorption under the condition of relatively low humidity, wherein the weight gain of eutectic form A by moisture absorption is not more than 1.08% when the relative humidity increases from 0 to 60% RH. Production conditions for eutectic form A are easy to control, same has a simple preparation process and a stable quality, and is easy to industrially produce on a large-scale.

Methods of treating cancer related conditions using anamorelin are described.